+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Taltz"

From
Global Psoriasis Treatment Market Outlook, 2031 - Product Thumbnail Image

Global Psoriasis Treatment Market Outlook, 2031

  • Report
  • March 2026
  • 209 Pages
  • Global
From
North America Psoriasis Treatment Market Outlook, 2031 - Product Thumbnail Image

North America Psoriasis Treatment Market Outlook, 2031

  • Report
  • March 2026
  • 88 Pages
  • North America
From
From
From
  • 8 Results (Page 1 of 1)
Loading Indicator

Taltz is a biologic drug used to treat moderate to severe plaque psoriasis in adults. It is a human interleukin-17A (IL-17A) inhibitor, which works by blocking the action of IL-17A, a protein that plays a role in the development of psoriasis. Taltz is administered as an injection under the skin, and is typically used in combination with other treatments such as topical medications and phototherapy. Taltz is one of several biologic drugs used to treat psoriasis, and is one of the most widely prescribed biologics for the condition. It is generally well-tolerated, with the most common side effects being injection site reactions, upper respiratory tract infections, and headache. The Taltz market is highly competitive, with several major pharmaceutical companies offering biologic drugs for the treatment of psoriasis. These include Eli Lilly, Novartis, AbbVie, Janssen, and Pfizer. Show Less Read more